Clinical outcomes provide new insights into transformation to small-cell lung cancer of pulmonary EGFR-mutant adenocarcinoma

Eric Santoni-Rugiu


Despite very high response rate (RR) and significant clinical benefit of EGFR-tyrosine-kinase inhibitors (TKIs) in patients with advanced EGFR-mutated (EGFRM+) non-small cell lung cancer (NSCLC) of adenocarcinoma (LAC) type, virtually all cases become resistant to these drugs with a median progression-free survival (PFS) of 9–13 months.

Download Citation